Answers are grounded in this paper and cite their sources.
This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC.
No takes yet. Share an insight, caveat, or question.
Song et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: